H2O America vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? H2O America trades at $58.66 (market cap $2.43B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.59 (market cap $2.27B). The key difference: H2O America and SELLAS Life Sciences Group Inc. Common Stock are close in size by market cap, and H2O America pays a 3.03% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| HTO | SLS | |
|---|---|---|
Market Cap | $2.43B | $2.27B |
Volume | 593,883 | 4,179,659 |
Sector | Utilities | Health |
52-Week High | $65.43 | $15.46 |
52-Week Low | $44.44 | $1.39 |
Typical Hold Time | 40 Days | — |
Enterprise Value | $4.22B | $2.14B |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
HTO trades at $57.98, down 0.34% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 12.91% net margin and 6.46% ROE, supported by recent acquisitions in Texas water utilities. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target, representing 15% upside potential from current levels.
The stock offers attractive dividend yield with recent $0.44 dividend declaration, but faces execution risks from acquisition integration and negative cash flow from investing activities. Technical indicators show mixed signals with oversold RSI readings conflicting with bearish moving averages, creating potential entry opportunity for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →